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OBJECTIVE—Although adipocyte-derived murine resistin links
insulin resistance to obesity, the role of human resistin, pre-
dominantly expressed in mononuclear cells and induced by
inﬂammatory signals, remains unclear. Given the mounting
evidence that obesity and type 2 diabetes are inﬂammatory
diseases, we sought to determine the relationship between
inﬂammatory increases in human resistin and insulin resistance.
RESEARCH DESIGN AND METHODS—To investigate the
role of human resistin on glucose homeostasis in inﬂammatory
states, we generated mice lacking murine resistin but transgenic
for a bacterial artiﬁcial chromosome containing human resistin
(BAC-Retn), whose expression was similar to that in humans.
The metabolic and molecular phenotypes of BAC-Retn mice were
assessed after acute and chronic endotoxemia (i.e., exposure to
inﬂammatory lipopolysaccharide).
RESULTS—We found that BAC-Retn mice have circulating
resistin levels within the normal human range, and similar to
humans, lipopolysaccharide markedly increased serum resistin
levels. Acute endotoxemia caused hypoglycemia in mice lacking
murine resistin, and this was attenuated in BAC-Retn mice. In
addition, BAC-Retn mice developed severe hepatic insulin resis-
tance under chronic endotoxemia, accompanied by increased in-
ﬂammatory responses in liver and skeletal muscle.
CONCLUSIONS—These results strongly support the role of
human resistin in the development of insulin resistance in
inﬂammation. Thus, human resistin may link insulin resistance
to inﬂammatory diseases such as obesity, type 2 diabetes, and
atherosclerosis. Diabetes 60:775–783, 2011
T
he prevalence of obesity has increased world-
wide, and therefore, the burden of obesity on
health is progressively growing (1). Obesity is
associated with insulin resistance and an in-
creased risk of type 2 diabetes. Recently, it has become
clear that obesity promotes a state of chronic, low-grade
inﬂammation in white adipose tissue (WAT), which leads
to insulin resistance. Adipocytes and macrophages in WAT
both are involved in the development of insulin resistance
in obesity through the release of free fatty acids (FFAs),
proinﬂammatory cytokines, and adipokines (2–4).
Resistin, predominantly expressed in adipocytes, medi-
ates insulin resistance in rodents. Circulating levels of
resistin are increased in obesity, and treatment with recom-
binant resistin or transgenic overexpression of resistin
induces hepatic insulin resistance in mice (5–8). Further-
more, deletion of resistin enhances insulin sensitivity in
livers of mice fed a high-fat diet, and in muscle and WAT in
leptin-deﬁcient ob/ob mice (9,10). In contrast, resistin is
mainly expressed in mononuclear cells, including macro-
phages in humans (11,12). Human resistin is induced in
response to various inﬂammatory stimuli such as lipopoly-
saccharide (LPS), tumor necrosis factor-a (TNF-a), or in-
terleukin (IL)-6, and resistin itself induces proinﬂammatory
cytokines, suggesting a role for resistin in inﬂammation in
humans (13–16). Moreover, circulating resistin levels
correlate with inﬂammatory markers in subjects with
type 2 diabetes, coronary atherosclerosis, chronic kidney
disease, rheumatoid arthritis, sepsis, and experimental
endotoxemia (14,17–21).
Because it is widely accepted that obesity and type 2
diabetes are associated with chronic inﬂammation in WAT,
and resistin is produced by macrophages in inﬂammation,
hyperresistinemia might be a contributing factor to these
pathophysiologic states in humans. However, studies re-
lating resistin in humans to obesity, insulin resistance, or
type 2 diabetes have shown conﬂicting results (22–28).
Therefore, it remains uncertain whether the role of
adipocyte-derived murine resistin in glucose homeostasis
translates directly to the biology of macrophage-derived
human resistin.
We have previously demonstrated that transgenic ex-
pression of human resistin in resistin-knockout (Rko) mice
fed a high-fat diet results in insulin resistance in muscle
and adipose tissue, indicating that macrophage-derived
human resistin exacerbates insulin resistance (29). How-
ever, macrophage human resistin expression in that model
was constitutive and not induced by inﬂammatory stimuli.
Here we investigated the metabolic effects of human
resistin induced by inﬂammation using a novel transgenic
mouse that express human resistin from its human ge-
nomic elements (BAC-Retn mice). In contrast to the
previous macrophage-speciﬁc humanized resistin mice,
circulating resistin levels in this new BAC-Retn mouse are
similar to those in healthy humans but increase in re-
sponse to inﬂammatory signals such as LPS. Under ex-
perimental endotoxemia, BAC-Retn mice showed increased
inﬂammation and hepatic insulin resistance. Thus, with
a humanized expression pattern, human resistin con-
tributes to the development of insulin resistance in
inﬂammation.
RESEARCH DESIGN AND METHODS
Cell culture and transfections. The BAC-Retn construct that included the
human resistin gene plus 20 kb upstream and 4 kb downstream DNA regions
was engineered and transfected into mouse macrophage RAW.264 cells by
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ORIGINAL ARTICLEelectroporation according to the manufacturer’s instructions (Lonza, Allen-
dale, NJ). Primary mouse macrophages were obtained from male BAC-Retn
mice by peritoneal lavage 3 days after an intraperitoneal injection with 1 mL of
sterile 3% thioglycollate. RAW.264 cells or primary mouse macrophages were
stimulated with LPS for 16 h. Cells or media not exposed to LPS served as the
control. Human resistin gene expression was detected by quantitative PCR,
and protein in the media was determined by ELISA (Millipore Corporation,
Billerica, MA).
Derivation and treatment of animals. For the derivation of mice that ex-
press the human resistin under the control of the human resistin regulatory
DNA elements, we engineered a BAC as described previously (30). The
engineered BAC contained the whole human resistin gene, including 21,300 bp
upstream and 4,248 bp downstream of the human resistin start site. The fusion
construct containing human resistin and the 25,548 bp surrounding it was then
excised using NotI/BglII and injected into the pronucleus of fertilized C57BL/6
J mouse oocytes (Transgenic and Chimeric Mouse Facility, University of
Pennsylvania). Transgenic founder mice were identiﬁed by PCR of tail DNA
with the forward primer covering the 59 end of the human resistin exon (59-
ACCAGTCTCTGGACATGAAG-39) and the reverse primer covering the 39-end
of the human resistin exon (59-TCGGTGGGCTCAGCTAACCA-39). Positive mice
were propagated by mating to Retn
2/2 mice (9). The progeny (Retn
+/2BAChR)
were then crossed back to the Retn
2/2 mice to produce the BAC-transgenic
(BAC-Retn) mice that express human resistin without expressing murine
resistin (Retn
2/2BAChR). Retn
2/2 littermates were used as controls in this
study.
Animalsusedinallexperimentswereage-matched(10-to12-week-old)male
mice housed four or ﬁve per cage under an ambient temperature of 22°C with
12 h light/dark cycle (lights on at 0700 h). Regular chow (LabDiet, Richmond,
IN) and water were provided ad libitum. All protocols for animal use and eu-
thanasia were approved by the Institutional Animal Care and Use Committee of
the University of Pennsylvania School of Medicine and were in accordance
with National Institutes of Health guidelines.
LPS administration. Mice were weighed to determine the dose of LPS
(Escherichia coli O 111:B4; Sigma-Aldrich, St. Louis, MO). For acute endo-
toxemia experiments, equivalent volumes of LPS (0.2 mg/kg body wt) or
normal saline (0.9%) were intraperitoneally injected to both Rko and BAC-Retn
mice. Blood was collected before and at 1, 3, and 6 h after injection. For
chronic endotoxemia experiments, mice were implanted subcutaneously with
an osmotic minipump (Alzet model 1002; Braintree Scientiﬁc Inc., Braintree,
MA) as previously described (31). The pumps were ﬁlled with normal saline or
LPS to infuse 2 mg/kg/day for 2 weeks.
Total RNA extraction and quantitative PCR. Mice were killed and their
tissues isolated and immediately placed in liquid nitrogen for later use. Total
RNA from tissues wasextractedusingTrizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. RNA integrity was determined
with ultraviolet spectrophotometry. Reverse transcription was performed with
Sprint RT complete-Oligo(dT)18 (Clontech Laboratories, Mountain View, CA)
according to the manufacturer’s instructions. Expression of genes was ana-
lyzed using real-time (TaqMan) quantitative PCR (ABI Prism; Applied Bio-
systems, Foster City, CA) as previously described (29). The level of mRNA
expression was normalized to 36B4.
Measurement of serum and tissue metabolites. Blood glucose measure-
mentswereobtainedfromtailveinbloodusingtheOneTouchUltraGlucometer
(Lifescan, Milpitas, CA). Serum was harvested by tail vein blood or cardiac
puncture, spun at 4°C for 30 min, and assayed immediately or stored at 220°C.
Serum alanine aminotransferase (ALT), TGs, cholesterol, b-hydroxybutyric
acid, and FFAs levels were measured using colorimetric assays (Stanbio
Laboratory, Boerne, TX; Wako Pure Chemical Industries, Osaka, Japan). Se-
rum mouse insulin, resistin, leptin, high-molecular-weight adiponectin, and
human resistin levels were measured by ELISA (Crystal Chem Inc., Downers
Grove, IL; Millipore Corporation, Billerica, MA). Serum TNF-a and IL1b levels
were measured with Luminex-100 multiplex immunoassay (Millipore). Lipids
were extracted from liver for TGs and cholesterol measurements, as pre-
viously described (32). For diacylglycerol and ceramides levels, 100-mg sam-
ples of liver tissue were submitted to the Mouse Metabolic Phenotyping Center
at Yale Medical School (New Haven, CT).
Glucose tolerance test. On the 8th day after the minipump subcutaneous
implantation, glucose tolerance testing was performed after an 8-h fast. Blood
glucose concentrations were measured before and at 15, 30, 60, 90, and 120 min
after an intraperitoneal injection of glucose (1 g/kg, 20% glucose solution). Tail
blood samples collected before the glucose injection were used to measure
basal levels of mouse insulin and human resistin.
Hyperinsulinemic-euglycemic clamp. Hyperinsulinemic-euglycemic clamp
analysis was performed as described previously (29). Clamp studies were
performed at 6 h after LPS (0.2 mg/kg) or saline intraperitoneal injection, and
also at 10 days after the minipump subcutaneous implantation. Mice were
fasted for 4 h, placed in restrainers, and administered a bolus injection of
5 mCi of [3-3H]glucose, followed by continuous intravenous infusion at 0.05
mCi/min. Baseline glucose kinetics was measured for 60 min, followed by
hyperinsulinemic clamp for 120 min. A priming dose of regular insulin (16 mU/
kg, Humulin; Eli Lilly, Indianapolis, IN) was given intravenously, followed by
continuous infusion at 2.5 mU/kg/min. Tail blood glucose was measured by
glucometer at 10-min intervals, and blood glucose was maintained at 120–140
mg/dL by a variable infusion rate of 20% glucose. 2-Deoxy-D-[1-14C]glucose
(10 mCi) was injected 45 min before the end of the clamp, and blood samples
were collected to estimate glucose uptake. The mice were killed, and liver,
perigonadal WAT, and gastrocnemius muscle were excised, frozen immedi-
ately in liquid nitrogen, and stored at 280°C for subsequent analysis of glucose
uptake and other analysis.
Statistics. Data are presented as means 6 SEM. Changes of various param-
eters were analyzed with one-way ANOVA, followed by post hoc Tukey mul-
tiple comparison test or unpaired Student t test using Prism software
(GraphPad Software, San Diego, CA). Values of P , 0.05 were considered as
statistically signiﬁcant.
RESULTS
Generation of mice that express human resistin with
human-like inducible regulation. We generated a BAC
that contains the human resistin gene plus all the DNA
elements up to 21,300 bp upstream and 4,248 bp down-
stream relative to the human resistin start site (Fig. 1A).
Human resistin was basally expressed and markedly in-
duced by LPS treatment of RAW.264 murine macrophages
transfected with this BAC fusion construct (Fig. 1B and C).
To better understand the role of human resistin in the
pathophysiology of inﬂammation and metabolism, we then
derived transgenic mice on the C57BL/6 J Rko background
using the BAC fusion construct (BAC-Retn mice). The
expression pattern of human resistin in BAC-Retn mice
was similar to that seen in humans, with the highest ex-
pression seen in bone marrow (Fig. 1D) (11). Moreover,
human resistin expression was dramatically induced in
peritoneal macrophages isolated from BAC-Retn mice
(Fig. 1E).
LPS-induced hypoglycemia is less severe in BAC-Retn
mice. In the mice fed normal chow, there were no ap-
preciable differences between Rko and BAC-Retn mice in
serum levels of TGs, FFAs, ketone, adiponectin, or leptin.
LPS increased serum alanine aminotransferase (ALT),
FFA, and leptin levels in both groups and decreased serum
total and high-molecular-weight adiponectin levels (Table 1).
Circulating levels of human resistin increased about
ﬁvefold from baseline within 6 h after LPS injection in
BAC-Retn mice, which was consistent with the robust in-
crease in human resistin expression and secretion ob-
served in blood mononuclear cells (Fig. 2A and B). As has
been previously described (33), LPS injection caused hy-
poglycemia acutely. Although LPS induced similar increases
in serum TNF-a and IL1b levels in Rko and BAC-Retn mice
(Fig. 2C and D), hypoglycemia was less severe in BAC-
Retn compared with Rko mice (100 6 6v s .7 76 6 mg/dL,
P , 0 . 0 5 ;F i g .2 E). Serum insulin levels were not different
between groups (P = 0.32), suggesting human resistin
attenuated hypoglycemia in acute endotoxemia via in-
sulin resistance (Fig. 2F).
Insulin resistance in BAC-Retn mice in acute
endotoxemia. To examine the role of human resistin in
glucose homeostasis in acute endotoxemia, we performed
hyperinsulinemic-euglycemic clamp studies after LPS or
saline injection. Compared with saline injection, LPS
acutely suppressed the basal rate of hepatic glucose pro-
duction in Rko mice by 61%, and in BAC-Retn mice by 40%
(Supplementary Fig. 1A). The glucose infusion rate re-
quired to maintain euglycemia was 31% lower in BAC-Retn
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more insulin resistant during acute endotoxemia (Fig. 3A).
Hepatic insulin resistance in acute endotoxemia was
manifested by a higher rate of glucose production (HGP) in
BAC-Retn mice compared with Rko mice (Fig. 3B). In
support of this result, both glucose-6-phosphatase (G6pase)
and PEPCK expression levels were slightly higher in BAC-
Retn mice than in Rko mice under clamp studies in acute
endotoxemia, although the differences did not reach sta-
tistical signiﬁcance (Supplementary Fig. 1B and C). Al-
though the whole-body rate of glucose disposal (Rd) was
not different between both groups, insulin-stimulated glu-
cose uptake in WAT was 46% lower in BAC-Retn mice
(Fig. 3C–E). Impaired glucose uptake in WAT in BAC-Retn
mice was also consistent with signiﬁcantly higher serum
FFA levels compared with Rko mice, indicating less sup-
pression of lipolysis by insulin during hyperinsulinemic
clamp studies (0.13 6 0.03 vs. 0.07 6 0.03 mEq/L, P , 0.05).
To understand the possible mechanism of hepatic in-
sulin resistance, we next measured lipids content in liver.
Compared with Rko mice, BAC-Retn mice had a 24%
higher total ceramides content in liver (Fig. 3F) during
acute endotoxemia, with most ceramide species being el-
evated (Supplementary Fig. 1D). Moreover, there was a
signiﬁcant correlation between hepatic ceramide content
and HGP during hyperinsulinemic clamp studies (r = 0.77,
P , 0.01; Fig. 3G). However, there were no differences in
hepatic diacylglycerol and TG levels between Rko and
BAC-Retn mice (Supplementary Fig. 1E and F). Despite
the changes in hepatic ceramide content, there were no
differences in the expression of several genes involved in
pathways of ceramide generation and salvage between
Rko and BAC-Retn mice (Supplementary Fig. 1G) (34).
Impaired glucose tolerance in BAC-Retn mice in
chronic endotoxemia. BAC-Retn mice were studied un-
der chronic experimental endotoxemia to mimic the
chronic inﬂammation of obesity and type 2 diabetes. Body
weight and blood glucose of chronic LPS-infused mice
signiﬁcantly decreased initially, similar to the effect of
acute endotoxemia described above, but recovered later
(Supplementary Fig. 2A and B). During chronic endotox-
emia, glucose tolerance in BAC-Retn mice was signiﬁ-
cantly impaired relative to the Rko mice (Fig. 4A), while
circulating resistin levels rose approximately fourfold in
these mice (Fig. 4B). Serum insulin, TNF-a and IL1b levels
were not different in both groups, suggesting that human
resistin is responsible for glucose intolerance in chronic
endotoxemia (Fig. 4C; Supplementary Fig. 2C and D).
FIG. 1. Generation and characterization of BAC-transgenic (BAC-Retn) mice. A: A BAC that contains the human resistin gene plus all the DNA
elements up to 21,300 bp upstream and 4,248 bp downstream relative to the human resistin start site is used to generate the mice. The fusion
construct was excised using NotI/BglII and injected into the pronucleus of fertilized C57BL/6 J mouse oocytes. B: Induction of human resistin gene
by LPS (100 ng/mL) in transfected RAW.264 macrophages. C: LPS (100 ng/mL) induced secretion of resistin in transfected RAW.264 macrophages.
D: Expression proﬁle of human resistin in different tissues in BAC-Retn mice. E: LPS induced human resistin in vitro in peritoneal macrophages
from BAC-Retn mice (n = 5 per group). Data are presented with the SEM. BAT, brown adipose tissue; BM, bone marrow; L. int, large intestine;
PBMC, peripheral blood mononuclear cells; S. int, small intestine. *P < 0.05, **P < 0.01 vs. saline.
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chronic endotoxemia, we next performed gene-expression
analysis. BAC-Retn mice had increased expression of
proinﬂammatory cytokines as well as macrophage mark-
ers such as monocyte chemotactic protein-1 (MCP1) and
F4/80 in liver and skeletal muscle (Fig. 4D and E), in-
dicating resistin exacerbated inﬂammation and promoted
tissue inﬁltration of macrophages in chronic endotoxemia
but not in WAT (Supplementary Fig. 3). Although serum
levels of TGs, FFA, and total and high-molecular-weight
adiponectin decreased in chronic endotoxemia, there
were no differences between the Rko and BAC-Retn mice
(Table 2).
Hepatic insulin resistance in BAC-Retn mice in
chronic endotoxemia. To determine the mechanism un-
derlying the effect of humanized resistin induction on
glucose homeostasis in chronic endotoxemia, we per-
formed hyperinsulinemic-euglycemic clamp studies. The
glucose infusion rate required to maintain euglycemia was
signiﬁcantly lower in BAC-Retn than in Rko mice (Fig. 5A).
Although Rd was not different, HGP was 60% higher in
BAC-Retn mice, indicating that human resistin induced
severe hepatic insulin resistance in chronic endotoxemia
(Fig. 5B and C). To understand the mechanism of hepatic
insulin resistance, we examined gene-expression analysis
in liver under clamp studies. TNF-a expression was ap-
proximately threefold higher in liver of BAC-Retn mice,
suggesting resistin exacerbates inﬂammation in liver (Fig.
5D). Expression levels of G6pase and PEPCK were also
signiﬁcantly higher in BAC-Retn mice compared with Rko
mice (fourfold and twofold, respectively; Fig. 5E and F),
which is compatible with a higher rate of HGP in chronic
endotoxemia. Measurements of lipids content in liver
showed no differences in hepatic TG and total ceramides
content between Rko and BAC-Retn mice (Supplementary
Fig. 4A and B).
DISCUSSION
Murine resistin is secreted by adipocytes, whereas human
resistin is secreted by mononuclear cells. Although genetic
and pharmacologic studies strongly support links between
resistin, obesity, and insulin resistance in mice, the role
of human resistin as a modulator of metabolism in in-
ﬂammatory states is not well understood. The present
ﬁnding that induction of human resistin alters glucose
metabolism in endotoxemia clearly links human resistin to
inﬂammation-induced insulin resistance. Therefore, this
study provides much needed insight into the pathophysi-
ologic role of human resistin in various inﬂammatory
states associated with insulin resistance, ranging from
sepsis to type 2 diabetes and atherosclerosis. In this re-
spect, it is noteworthy that several epidemiologic studies
have recently showed close relationships between resistin
and type 2 diabetes, cardiovascular disease, and inﬂam-
matory markers (17,18,21,35).
Early stages of sepsis and experimental endotoxemia
are associated with hypoglycemia through increased glu-
cose disposal by macrophage-rich tissues as well as de-
creased glucose production in humans as well as animals
(33,36–38). In line with previous reports, LPS administra-
tion acutely caused hypoglycemia in Rko and BAC-Retn
mice, with similar robust increases in serum proin-
ﬂa m m a t o r yc y t o k i n e s ,w h i c ha r ek n o w nt oc a u s eh y -
poglycemia (33,36). LPS increased serum leptin levels
and decreased adiponectin, which can be explained by
cytokine responses (39–42). During acute LPS-induced
hypoglycemia, however, the induction of human resistin
increased hepatic glucose production and decreased glu-
cose uptake, thereby reducing the severity of hypoglycemia.
Intriguingly, mice lacking resistin are more prone to fasting-
induced hypoglycemia than wild-type mice (9), suggesting
similar functions of resistin across species, albeit in differ-
ent physiologic settings. Thus the human-speciﬁc expres-
sion pattern of resistin facilitates its function as a glucose
counterregulatory hormone to mitigate hypoglycemia dur-
ing acute endotoxemia. Of note, the metabolic effects of
chronic endotoxemia in wild-type mice (31) are likely through
a resistin-independent mechanism because murine resistin
is not induced by LPS (Supplementary Fig. 5A–C)( 4 3 , 4 4 ) ,
although it was recently reported to be induced by homo-
cysteine, which is proinﬂammatory among other pleiotropic
effects (45).
Animal studies on the acute effect of LPS on insulin
sensitivity have yielded conﬂicting results (46,47). In the
setting of acute endotoxemia, we found that insulin sen-
sitivity was enhanced in liver as well as in WAT of Rko
mice and that human resistin abrogated this insulin-
sensitizing effect of LPS, inducing insulin resistance. Our
ﬁnding that hepatic ceramide content correlated with he-
patic insulin resistance is consistent with a previous report
(48). Ceramide has been shown to induce insulin re-
sistance by inhibiting insulin signaling. Interestingly, TNF-
a can acutely stimulate the accumulation of ceramide and
TABLE 1
Serum metabolic proﬁle 6 h after LPS administration
Variable Rko-Saline BAC-Retn-Saline Rko-LPS BAC-Retn-LPS
Weight (g) 29.4 6 0.6 29.6 6 0.8 29.5 6 0.7 30.1 6 0.5
Triglyceride (mg/dL) 40.3 6 5.2 32.6 6 1.8 38.0 6 3.0 55.9 6 6.7*†
Cholesterol (mg/dL) 66.6 6 5.3 67.5 6 2.6 66.4 6 2.5 72.1 6 2.6
FFAs (mEq/L) 0.90 6 0.05 0.85 6 0.04 1.10 6 0.05‡ 1.22 6 0.13*
Ketone (mg/dL) 3.3 6 0.5 5.5 6 0.8 8.4 6 1.0‡ 7.2 6 0.6
Alanine aminotransferase (U/L) 12 6 11 4 6 12 5 6 2* 44 6 3*§
Adiponectin (mg/mL) 25.7 6 0.9 26.3 6 2.0 21.3 6 1.3‡ 20.2 6 1.5‡
HMW adiponectin (mg/mL) 3.70 6 0.13 3.45 6 0.36 2.45 6 0.28‡ 2.25 6 0.17‡
Leptin (ng/mL) 5.7 6 1.0 4.8 6 1.1 10.9 6 1.7‡ 10.6 6 1.4‡
LPS (0.2 mg/kg) or normal saline (0.9%) was intraperitoneally injected in 12-week-old, normal-chow-fed Rko and BAC-Retn mice (n =5 –7 per
group). Data are presented as means 6 SEM. BAC-Retn, BAC-transgenic; HMW, high-molecular-weight. *P , 0.01 vs. saline; †P , 0.05; ‡P ,
0.05; §P , 0.01 vs. Rko.
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not detect differences in ceramide-related gene expression
in liver of the BAC-Retn mice, the changes of hepatic
ceramide content in acute endotoxemia could be due to
changes in enzyme activity or to alterations in substrate ﬂux.
During chronic endotoxemia, induction of human
resistin promoted glucose intolerance and hepatic insulin
resistance, suggesting its role as a link between innate
immunity, inﬂammation, and insulin resistance. Epide-
miologic studies provide strong evidence that chronic
inﬂammation and obesity-induced insulin resistance are
closely related (50–53). Experimental endotoxemia in hu-
mans, akin to states of infection and sepsis, also induces
systemic insulin resistance as well as increased circulating
resistin (16,37,54). Here we found that, in mice, chronic
endotoxemia robustly induced inﬂammation in liver and
FIG. 2. Changes in resistin, cytokines, and glucose in acute endotoxemia in BAC-Retn mice. Acute LPS (0.2 mg/kg) or normal saline (0.9%) in-
traperitoneal administration to Rko (□) and BAC-Retn (■) mice (n =5 –7 per group). A and B: Human resistin was induced in response to LPS in
vivo in BAC-Retn mice. C and D: Serum TNF-a and IL1b levels increased similarly in Rko and BAC-Retn mice. E: LPS-induced hypoglycemia is less
severe in BAC-Retn than in Rko mice at 6 h after LPS injection. F: Serum insulin levels in 6 h after LPS injection. PBMC, peripheral blood
mononuclear cells. Data are presented with the SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline; #P < 0.05 vs. Rko.
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human resistin. Our ﬁnding that human resistin promotes
insulin resistance by inducing TNF-a and upregulating
G6pase and PEPCK in liver are consistent with previous
reports (15,55,56).
Although hepatic ceramide accumulation can at least
partly explain hepatic insulin resistance in acute endo-
toxemia, tissue inﬂammation exacerbated by resistin, not
hepatic ceramide, seems to be a plausible mechanism for
insulin resistance in chronic endotoxemia. Recently, reg-
ulatory T-cells have been demonstrated to contribute
to macrophage recruitment and adipose inﬂammation in
obesity, and resistin has been shown to indirectly enhance
regulatory T-cells (57,58). Thus, T-cells, in addition to
macrophages, may possibly be involved in the enhanced
inﬂammation of the BAC-Retn mice. It remains unanswered
FIG. 3. Acute endotoxemia induces hepatic and adipose tissue insulin resistance in BAC-Retn mice. A–C: Hyperinsulinemic-euglycemic clamp
analysis of BAC-Retn (■) vs. Rko (□) mice (n = 4 per group) in 6 h after LPS administration. D and E: Rate of insulin-stimulated glucose uptake in
WAT (D) and skeletal muscle (E). F: Total ceramides content in liver. G: Correlation between hepatic ceramide content and hepatic glucose
production (HGP) during the clamp study. Data are presented with the SEM. GIR, glucose infusion rate; Rd, whole-body rate of glucose disposal.
*P < 0.05 vs. saline; #P < 0.05 vs. Rko.
RESISTIN AND INSULIN RESISTANCE
780 DIABETES, VOL. 60, MARCH 2011 diabetes.diabetesjournals.orghow resistin functions in various tissues or cells, because
the receptor for resistin has not yet been uncovered.
In summary, we have demonstrated that human resistin
modulates glucose homeostasis under inﬂammation using
a humanized resistin mouse model. Human resistin is in-
duced in response to inﬂammation. Resistin attenuates
endotoxemia-induced hypoglycemia by inducing insulin
resistance in liver and WAT and promotes hepatic insulin
resistance by exacerbating inﬂammatory responses in
chronic endotoxemia. Increased inﬂammation is accom-
panied by increased inﬁltration of macrophages, which
can, in turn, augment resistin induction. Thus, induction
of resistin is expected to be a component of the patho-
physiology of inﬂammation-induced insulin resistance in
humans. The mouse model of humanized resistin ex-
pression reported here can be used to provide a better
understanding and potential amelioration of the metabolic
pathology of inﬂammatory states in humans.
FIG. 4. Impaired glucose tolerance and exacerbated inﬂammation in chronically endotoxemic BAC-Retn mice. A: With chronic LPS (2 mg/kg/day)
subcutaneous infusion, BAC-Retn mice show impaired glucose tolerance compared with Rko mice (n =5 –7 per group). B and C: Serum resistin (B)
and insulin (C) levels in Rko (□)a n dBAC-Retn (■) mice. D and E: Gene-expression analysis in liver (D) and skeletal muscle (E). Data are
presented with the SEM. GTT, glucose tolerance test; RETN, human resistin. *P < 0.05, **P < 0.01 vs. saline; #P < 0.05, ##P < 0.01 vs. Rko.
TABLE 2
Serum metabolic proﬁle in chronic endotoxemia
Variable Rko-Saline BAC-Retn-Saline Rko-LPS BAC-Retn-LPS
Weight (g) 28.0 6 0.4 26.8 6 0.8 26.2 6 0.2 25.8 6 0.3
Triglycerides (mg/dL) 85.7 6 5.4 70.2 6 1.5 64.0 6 6.3* 60.0 6 2.8*
Cholesterol (mg/dL) 80.8 6 4.2 73.7 6 1.2 72.3 6 1.7 62.9 6 5.2
FFAs (mEq/L) 0.77 6 0.07 0.84 6 0.08 0.41 6 0.07† 0.47 6 0.04*
Ketone (mg/dL) 2.6 6 0.3 3.2 6 0.8 2.0 6 0.3 1.9 6 0.1*
Alanine aminotransferase (U/L) 7 6 18 6 16 6 17 6 2
Adiponectin (mg/mL) 25.2 6 1.4 25.5 6 1.2 15.9 6 1.6† 15.3 6 0.7*
HMW adiponectin (mg/mL) 3.60 6 0.19 4.09 6 0.99 1.57 6 0.08† 1.59 6 0.11*
LPS (2 mg/kg/day) or normal saline (0.9%) was subcutaneously infused with a minipump to 10-week-old, normal-chow-fed Rko and BAC-Retn
mice for 10 days (n =5 –7 per group). Data are presented as means 6 SEM. BAC-Retn, BAC-transgenic; HMW, high-molecular-weight. *P ,
0.05; †P , 0.01 vs. saline.
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